Wright Therapy Services | |
2122 Osburn Rd Arrington TN 37014-9735 | |
(615) 613-2912 | |
Not Available |
Full Name | Wright Therapy Services |
---|---|
Speciality | Behavior Analyst |
Location | 2122 Osburn Rd, Arrington, Tennessee |
Authorized Official Name and Position | Brittany Wright (OWNER) |
Authorized Official Contact | 6156132912 |
Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
Mailing Address | Practice Location Address |
---|---|
Wright Therapy Services 2122 Osburn Rd Arrington TN 37014-9735 Ph: () - | Wright Therapy Services 2122 Osburn Rd Arrington TN 37014-9735 Ph: (615) 613-2912 |
NPI Number | 1851050330 |
---|---|
Provider Enumeration Date | 12/13/2021 |
Last Update Date | 12/13/2021 |
Certification Date | 12/13/2021 |
Identifier | Type | State | Issuer |
---|---|---|---|
1851050330 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103K00000X | Behavior Analyst | (* (Not Available)) | Primary |
News Archive
New research from the Hebrew University of Jerusalem shows that a carefully scheduled high-fat diet can lead to a reduction in body weight and a unique metabolism in which ingested fats are not stored, but rather used for energy at times when no food is available.
Officials also said that the online insurance exchange is attracting more Hispanic customers, a key constituency for the marketing effort. Also, in Minnesota, officials announce an effort to boost enrollment of young adults.
After an appendectomy, a quarter (24.8%) of all children wanted a stronger pain treatment in the first 24 hours after their operation.
For the first time, researchers at the University of California, San Diego School of Medicine have isolated and characterized the progenitor cells that eventually give rise to malignant hepatocellular carcinoma tumors - the most common form of liver cancer. The researchers found ways to identify and isolate the HCC progenitor cells long before actual tumors were apparent.
NewLink Genetics Corporation announced today that it has closed a $30 million Series C financing to accelerate the clinical development of its therapeutic cancer products. Total cash raised in 2009 under a combination of the previously announced Series D Preferred and the remaining shares in the Series C Preferred totaled just under $20 million.
› Verified 7 days ago